Mirxes (Ticker: 2629 HK) is a Singapore-headquartered company specializing in micro ribonucleic acid (miRNA) technology for developing diagnostic solutions for early disease screening, notably cancer. Its core product is GASTROClearTM, a blood-based test for gastric cancer. Mirxes plans to list on the Hong Kong Stock Exchange Main Board on May 23, 2025. The company is offering approximately 46.62 million shares at a fixed price of HKD23.3 per share, aiming to raise around HKD1.086 billion (approximately USD 138.9 million). Mirxes is listing under the HKEX rules for pre-revenue biotech companies. Key institutional investors, including Beijing Xunrui Enterprise Management Partnership and Evergreen Gate Limited, have reportedly committed cornerstone investments totaling approximately USD 57.92 million.